Diabetes, a disease that causes the body to increase glucose levels, may require blood sugar tests to determine a patienta s need for insulin.
Many studies have reported that periodontal disease is associated with diabetes, but its relation with impaired fasting glucose (IFG) has been understudied. This study investigated the relationship between chronic periodontitis, IFG, and diabetes in the U.S. population.
RESEARCH DESIGN AND METHODS
Participants in the National Health and Nutrition Examination Survey III, aged ≥20 years, who received periodontal examinations and provided blood samples (n = 12,254) were grouped into quintiles of mean clinical attachment loss (CAL) and pocket depth, with the lowest category being the reference. Plasma fasting glucose was categorized into three groups (normal, <100 mg/dL; IFG, ≥100 but <126 mg/dL; and diabetic, ≥126 mg/dL). Sociodemographic factors and other potential risk factors were obtained by interview or examination. SAS 9.1 was used for statistical analysis accounting for the complex weighted sampling.
Participants in the top quintile category of CAL had higher prevalence odds of IFG (odds ratio [OR] 1.55 [95% CI 1.16–2.07]) and diabetes (4.77 [2.69–8.46]) after adjustment for related confounders, compared with those in the bottom quintile. The highest quintile of pocket depth was positively associated with IFG (1.39 [1.00–1.92]) and diabetes (1.63 [1.10–2.42]) compared with the lowest quintile. ORs for CAL increased from the lowest to the highest quintile (P value test for trend <0.01) for all outcomes. The ORs for pocket depth also tended to rise across quintiles.
Chronic periodontitis measured by CAL and pocket depth was positively associated in a linear relation with IFG and diabetes in U.S. adults.
The objective of this study was to evaluate the performance of blood glucose meters in diabetes associated with pregnancy (DP).
RESEARCH DESIGN AND METHODS
Finger-prick blood glucose levels measured using six different glucose meters on 102 patients with DP attending an antenatal clinic were compared with laboratory plasma glucose results. HbA1c and hematocrit were also measured.
The plasma glucose range was 2.2–9.4 mmol/L with hematocrit 33–37% and mean HbA1c 5.5% ± 0.56 (SD). All meters provided plasma equivalent results except one, which reported whole blood glucose that was adjusted to plasma equivalent values. The absolute glucose difference [meter – plasma glucose] was 0.232 ± 0.69 to 0.725 ± 0.62 mmol/L mean ± SD and bias ranged from 6.1 to 15.8%. Two meters were affected by hematocrit <36% (P < 0.05).
Blood glucose meters in current use are not optimally accurate when compared with plasma glucose measurement in DP. Recognition of this deviation is essential to prevent inappropriate treatment of DP.
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1C Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials
Insulin analogs are increasingly used in patients with type 2 diabetes. We compared the effect of basal, biphasic, prandial, and basal-bolus insulin regimens with insulin analogs to reach the hemoglobin A1C target of <7% in people with type 2 diabetes.
RESEARCH DESIGN AND METHODS
We conducted an electronic search for randomized controlled trials (RCTs) involving insulin analogs. RCTs were included if they lasted at least 12 weeks, reported the proportion of diabetic patients reaching the A1C target of <7% (primary outcome), and the number of patients in any arm was >30.
We found 16 RCTs, with 20 comparisons and 7,759 patients. A greater proportion of patients achieved the A1C goal of <7% with both biphasic (odds ratio 1.88 [95% CI 1.38–2.55]) and prandial (2.07 [1.16–3.69]) insulin compared with basal insulin; this was associated for biphasic insulin with greater hypoglycemia (event/patient/30 days, mean difference, 0.34 [range 0–0.69]) and weight gain in kg (1.0 kg [0.28–1.73]). Compared with biphasic insulin, the basal-bolus regimen was associated with a greater chance to reach the A1C goal (odds ratio 1.75 [95% CI 1.11–2.77]), with no greater hypoglycemia or weight gain. The effect of insulin analogs on long-term diabetes complications is still lacking.
A greater proportion of type 2 diabetic patients can achieve the A1C goal <7% with biphasic or prandial insulin compared with basal insulin; in absolute terms, the basal-bolus regimen was best for the attainment of the A1C goal.
If you are a Type 1 Diabetic chances are you have heard doctors, nurses, friends and family rave about how fantastic Insulin Pump Therapy would be for you. The brochures you picked up have happy smiling people in them. You’ve seen the DVDs extolling the benefits of wearing a pump.
FDA- Recall Due to Potential Microbial Contamination: Triad Alcohol Prep Pads, Alcohol Swabs, and Alcohol Swabsticks
Triad Group, a manufacturer of over-the-counter products and FDA notified healthcare professiona… [ January 7, 2011 ]
Approximately 19 million U.S. adults reported receiving treatment for diabetes in 2007, more than double the 9 million who said they received care in 1996, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. AHRQ also found that between 1996 and 2007: The number of people age 65 and [...]
Treating diabetes is hard enough. Don’t make it harder by starving your body of the nutrients it needs to work properly. Research has shown decisive evidence supporting key vitamins for hypoglycemia can dramatically improve your success against this disease.